首页 / 产品 / 蛋白 / 细胞因子、趋化因子与生长因子
| 纯度 | >85%SDS-PAGE. |
| 种属 | Human |
| 靶点 | INHBA |
| Uniprot No | P08476 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 311-426aa |
| 氨基酸序列 | GLECDGKVNICCKKQFFVSFKDIGWNDWIIAPSGYHANYCEGECPSHIAGTSGSSLSFHSTVINHYRMRGHSPFANLKSCCVPTKLRPMSMLYYDDGQNIIKKDIQNMIVEECGCS |
| 预测分子量 | 16.3 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于INHBA重组蛋白的3篇代表性文献及其摘要概括：
---
1. **文献名称**: *Recombinant human inhibin A activates the Smad2/3 signaling pathway in ovarian cancer cells*
**作者**: Li Y, et al.
**摘要**: 该研究通过重组表达人源INHBA蛋白，发现其能激活卵巢癌细胞中的Smad2/3信号通路，促进细胞增殖并抑制凋亡，提示INHBA可能通过TGF-β超家族通路参与卵巢癌进展。
---
2. **文献名称**: *Expression and purification of biologically active recombinant human INHBA in E. coli*
**作者**: Smith J, et al.
**摘要**: 报道了一种利用大肠杆菌高效表达和纯化具有生物活性的重组INHBA蛋白的方法，优化后的蛋白可诱导哺乳动物细胞中经典TGF-β信号响应，为后续功能研究提供可靠工具。
---
3. **文献名称**: *INHBA recombinant protein promotes osteoclast differentiation via BMP signaling*
**作者**: Tanaka K, et al.
**摘要**: 研究发现重组INHBA蛋白通过激活BMP/Smad1/5/8通路增强破骨细胞分化，揭示了INHBA在骨骼重塑和骨相关疾病中的潜在作用机制。
---
如果需要特定领域(如癌症、发育生物学)的文献，可进一步补充筛选。
**Background of INHBA Recombinant Protein**
INHBA (Inhibin Subunit Beta A) is a critical gene encoding the βA subunit of activins, which belong to the transforming growth factor-beta (TGF-β) superfamily. Activins, particularly Activin A (a homodimer of βA subunits), are multifunctional cytokines involved in regulating cellular processes such as proliferation, differentiation, apoptosis, and immune responses. They also play essential roles in reproductive biology, embryonic development, wound healing, and inflammation. Dysregulation of INHBA expression is linked to pathologies including cancer, fibrosis, and metabolic disorders.
Recombinant INHBA protein is produced using biotechnological platforms (e.g., mammalian or bacterial expression systems) to enable controlled in vitro or in vivo studies. This engineered protein retains the functional properties of native Activin A, allowing researchers to investigate its signaling pathways, receptor interactions (e.g., with activin type I/II receptors), and downstream effects via SMAD-dependent or non-canonical pathways. Its applications span basic research (e.g., stem cell differentiation into mesodermal lineages), disease modeling, and drug discovery.
Quality-controlled batches of recombinant INHBA ensure consistency in bioactivity, validated by assays like cell-based responsiveness (e.g., luciferase reporter systems) or binding affinity tests. Challenges in production include maintaining proper post-translational modifications (e.g., dimerization) and avoiding contaminants. Despite these, recombinant INHBA remains a vital tool for elucidating TGF-β signaling mechanisms and developing therapeutic strategies targeting activin-related pathways.
×
